The AR expression of SHL (100 μg/mL, 0.66-fold; 200 μg/mL, 0.54-fold) was similar to that of enzalutamide (0.69-fold), which is an anti-cancer agent and AR inhibitor (Figure 1). The gene discussed is SERHL; the disease is cancer.